Study # AZD5305 - D9723C00001

A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)

Study Status:

Enrolling

Treatment Agent:

Saruparib, Abiraterone Acetate, Darolutamide, Enzalutamide

Description

Short Title: EVoPAR - Prostate 01  

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

Resources and Links

National Clinical Trial Identified Number: NCT06120491

Information and next steps

Disease:

  • Metastatic Castration-Sensitive Prostate Cancer,
  • Prostate Cancer

Study Phase:

III

Physician Name:

Department:

Ask a Question